Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anti-Cancer Immunity in PatientsNeoadjuvant Intravenous Pexa Vec Therapy in Cancer Patients

Overview of attention for article published in Cancer Immunology Research, April 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)

Mentioned by

twitter: 6 X users

Readers on

mendeley: 39 Mendeley

So far, Altmetric has seen 10 X posts from 6 X users, with an upper bound of 6,775 followers.

RRIDs were included in the Cancer Immunology Research paper "Neoadjuvant Intravenous Oncolytic Vaccinia Virus T…" (https://t.co/0F5SDRcw1U). RRIDs like this improve reproducibility in scientific research. #ReproducibleResearch #STMpublishing

This study demonstrates the efficacy of an engineered oncolytic Vaccinia virus in patients with #MetastaticCancers, by Adel Samson, Alan Anthoney, Alan Melcher, Fiona Collinson et al. Take a look here: https://t.co/AxZSzW10VO https://t.co/dqHoXcwja2

#ICYMI: Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anti-Cancer Immunity in Patients by Samson, Anthoney, Melcher, Collinson et al. https://t.co/jaW2bvTvQl @UniversityLeeds https://t.co/x9sa5KH1tl

#OnlineFirst: Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anti-Cancer Immunity in Patients by Samson, Anthoney, Melcher, Collinson et al. https://t.co/Ho2TdTTSLj @UniversityLeeds https://t.co/4JqEHqKOT6

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 6 additional X posts.